Contribution of GTPase activity to LRRK2-associated Parkinson disease

Small GTPases

Volumn 4, Issue 3, 2013, Pages

  Tsika, Elpida ^a   Moore, Darren J ^a  

^a EPFL   (Switzerland)

Author keywords

Animal models; Autophagy; LRRK2; Microtubules; Neurite outgrowth; Neuronal cell death; Neuronal toxicity; PARK8; Parkinson's disease; Parkinsonism; Protein aggregation; Protein kinase

Indexed keywords

GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AUTOPHOSPHORYLATION; DIMERIZATION; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; LRRK2 GENE; MOLECULAR PATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ANALYSIS; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM;

GTP PHOSPHOHYDROLASES; HUMANS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES;

EID: 84887528093     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.25130     Document Type: Review

References (65)

1. Gasser T. Mendelian forms of Parkinson's disease. Biochim Biophys Acta 2009; 1792:587-96;PMID:19168133; http://dx.doi.org/10.1016/j.bba-dis.2008.12.007
2. Thomas B, Beal M F. Parkinson's disease. Hum Mol Genet 2007; 16 Spec No. 2:R183-94;PMID:17911161; http://dx.doi.org/10.1093/hmg/ddm159
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-40;PMID:9278044;http://dx.doi.org/10.1038/42166
4. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010; 68:201-6;PMID:20955928;http://dx.doi.org/10.1016/j.neuron.2010.10.014
5. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51:296-301;PMID:11891824;http://dx.doi.org/10.1002/ana.10113
6. Paisán-Ruíz C, Jain S, Evans EW, Gilks W P, Simón J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44:595-600;PMID:15541308;http://dx.doi.org/10.1016/j.neuron.2004.10.023
7. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44:601-607;PMID:15541309;http://dx.doi.org/10.1016/j.neuron.2004.11.005
8. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41:1308-1312;PMID:19915575;http://dx.doi.org/10.1038/ng.487
9. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41:1303-7;PMID:19915576;http://dx.doi.org/10.1038/ng.485
10. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al.; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic pen-etrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7:583-590;PMID:18539534;http://dx.doi.org/10.1016/S1474-4422(08)70117-0
11. Tsika E, Moore DJ. Mechanisms of LRRK2-mediated neurodegeneration. Curr Neurol Neurosci Rep 2012; 12:251-260;PMID:22441981;http://dx.doi.org/10.1007/s11910-012-0265-8
12. Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, Lincoln SJ, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006; 67:1506-1508;PMID:17060589;http://dx.doi.org/10.1212/01.wnl.0000240220.33950.0c
13. Wszolek ZK, Pfeiffer R F, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62:1619-1622;PMID:15136696;http://dx.doi.org/10.1212/01.WNL.0000125015.06989.DB
14. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006; 59:388-393;PMID:16437559;http://dx.doi.org/10.1002/ana.20731
15. Bosgraaf L, Van Haastert PJM. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 2003; 1643:5-10;PMID:14654223;http://dx.doi.org/10.1016/j.bbamcr.2003.08.008
16. Marín I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 2006; 23:2423-33;PMID:16966681;http://dx.doi.org/10.1093/molbev/msl114
17. Goldberg JM, Bosgraaf L, Van Haastert PJM, Smith JL. Identification of four candidate cGMP targets in Dictyostelium. Proc Natl Acad Sci U S A 2002; 99:6749-6754;PMID:12011437;http://dx.doi.org/10.1073/pnas.102167299
18. Marín I, van Egmond WN, van Haastert PJM. The Roco protein family: a functional perspective. FASEB J 2008; 22:3103-3110;PMID:18523161;http://dx.doi.org/10.1096/fj.08-111310
19. Taymans JM. The GTPase function of LRRK2. Biochem Soc Trans 2012; 40:1063-1069;PMID:22988866;http://dx.doi.org/10.1042/BST20120133
20. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009; 18:4022-34;PMID:19640926;http://dx.doi.org/10.1093/hmg/ddp346
21. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006; 60:557-569;PMID:17120249;http://dx.doi.org/10.1002/ana.21019
22. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006; 52:587-593;PMID:17114044;http://dx.doi.org/10.1016/j.neuron.2006.10.008
23. Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, Miskiewicz K, et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endo-cytosis. Neuron 2012; 75:1008-1021;PMID:22998870;http://dx.doi.org/10.1016/j.neuron.2012.08.022
24. Berwick DC, Harvey K. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum Mol Genet 2012; 21:4966-79;PMID:22899650;http://dx.doi.org/10.1093/hmg/dds342
25. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010; 466:637-641;PMID:20671708;http://dx.doi.org/10.1038/nature09191
26. Aasly JO, Vilariño-Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov Disord 2010; 25:2156-2163;PMID:20669305;http://dx.doi.org/10.1002/mds.23265
27. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 2007; 46:1380-1388;PMID:17260967;http://dx.doi.org/10.1021/bi061960m
28. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007; 357:668-671;PMID:17442267;http://dx.doi.org/10.1016/j.bbrc.2007.04.006
29. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 2007; 103:238-247;PMID:17623048
30. Liu M, Dobson B, Glicksman MA, Yue Z, Stein RL. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 2010; 49:2008-2017;PMID:20146535;http://dx.doi.org/10.1021/bi901851y
31. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006; 9:1231-1233;PMID:16980962;http://dx.doi.org/10.1038/nn1776
32. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007; 16:223-232;PMID:17200152;http://dx.doi.org/10.1093/hmg/ddl471
33. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, et al. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 2010; 6:e1000902;PMID:20386743;http://dx.doi.org/10.1371/journal.pgen.1000902
34. Daniëls V, Vancraenenbroeck R, Law BMH, Greggio E, Lobbestael E, Gao F, et al. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 2011; 116:304-315;PMID:21073465;http://dx.doi.org/10.1111/j.1471-4159.2010.07105.x
35. Biosa A, Trancikova A, Civiero L, Glauser L, Bubacco L, Greggio E, et al. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Hum Mol Genet 2013; 22:1140-1156;PMID:23241358;http://dx.doi.org/10.1093/hmg/dds522
36. Taymans JM, Vancraenenbroeck R, Ollikainen P, Beilina A, Lobbestael E, De Maeyer M, et al. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 2011; 6:e23207;PMID:21858031;http://dx.doi.org/10.1371/journal.pone.0023207
37. Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ. GTPase activity and neuronal toxic-ity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 2012; 8:e1002526;PMID:22363216;http://dx.doi.org/10.1371/journal.pgen.1002526
38. Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci 2012; 32:3877-3886;PMID:22423108;http://dx.doi.org/10.1523/JNEUROSCI.4566-11.2012
39. Berger Z, Smith KA, Lavoie MJ. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 2010; 49:5511-5123;PMID:20515039;http://dx.doi.org/10.1021/bi100157u
40. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008; 105:1499-1504;PMID:18230735;http://dx.doi.org/10.1073/pnas.0709098105
41. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniëls V, et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophos-phorylation. J Biol Chem 2008; 283:16906-16914;PMID:18397888;http://dx.doi.org/10.1074/jbc.M708718200
42. Sen S, Webber PJ, West AB. Dependence of leu-cine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 2009; 284:36346-36356;PMID:19826009;http://dx.doi.org/10.1074/jbc.M109.025437
43. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJM, Wittinghofer A. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homo-logue of the human LRRK2 Parkinson kinase. EMBO J 2008; 27:2239-2249;PMID:18650931;http://dx.doi.org/10.1038/emboj.2008.150
44. Jorgensen ND, Peng Y, Ho CCY, Rideout HJ, Petrey D, Liu P, et al. The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 2009; 4:e8463;PMID:20041156;http://dx.doi.org/10.1371/journal.pone.0008463
45. Gasper R, Meyer S, Gotthardt K, Sirajuddin M, Wittinghofer A. It takes two to tango: regulation of G proteins by dimerization. Nat Rev Mol Cell Biol 2009; 10:423-429;PMID:19424291;http://dx.doi.org/10.1038/nrm2689
46. Leung IWL, Lassam N. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J Biol Chem 1998; 273:32408-32415;PMID:9829970;http://dx.doi.org/10.1074/jbc.273.49.32408
47. Haebig K, Gloeckner CJ, Miralles MG, Gillardon F, Schulte C, Riess O, et al. ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS One 2010; 5:e13762;PMID:21048939;http://dx.doi.org/10.1371/journal.pone.0013762
48. Shiba Y, Randazzo PA. ArfGAP1 function in COPI mediated membrane traffic: currently debated models and comparison to other coat-binding ArfGAPs. Histol Histopathol 2012; 27:1143-1153;PMID:22806901
49. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006; 15:223-232;PMID:16321986;http://dx.doi.org/10.1093/hmg/ddi439
50. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006; 23:329-341;PMID:16750377;http://dx.doi.org/10.1016/j.nbd.2006.04.001
51. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, et al. LRRK2 phosphory-lates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007; 405:307-317;PMID:17447891;http://dx.doi.org/10.1042/BJ20070209
52. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005; 102:16842-16847;PMID:16269541;http://dx.doi.org/10.1073/pnas.0507360102
53. Gloeckner CJ, Boldt K, von Zweydorf F, Helm S, Wiesent L, Sarioglu H, et al. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res 2010; 9:1738-17345;PMID:20108944;http://dx.doi.org/10.1021/pr9008578
54. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, Beilina A, et al. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 2009; 389:449-454;PMID:19733152;http://dx.doi.org/10.1016/j.bbrc.2009.08.163
55. Kamikawaji S, Ito G, Iwatsubo T. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009; 48:10963-10975;PMID:19824698;http://dx.doi.org/10.1021/bi9011379
56. Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 2011; 412:94-110; PMID:21806997;http://dx.doi.org/10.1016/j.jmb.2011.07.033
57. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, et al. Ser1292 autophosphoryla-tion is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Trans Med 2012; 4:164ra161.
58. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010; 16:998-1000;PMID:20729864;http://dx.doi.org/10.1038/nm.2199
59. Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol 2011; 6:1021-1028;PMID:21812418;http://dx.doi.org/10.1021/cb2002413
60. Dusonchet J, Kochubey O, Stafa K, Young SM Jr., Zufferey R, Moore DJ, et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 2011; 31:907-912;PMID:21248115;http://dx.doi.org/10.1523/JNEUROSCI.5092-10.2011
61. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009; 1:e00002;PMID:19570025;http://dx.doi.org/10.1042/AN20090007
62. Li Y, Liu W, Oo T F, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009; 12:826-828;PMID:19503083;http://dx.doi.org/10.1038/nn.2349
63. Ramonet D, Daher J P, Lin BM, Stafa K, Kim J, Banerjee R, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011; 6:e18568;PMID:21494637;http://dx.doi.org/10.1371/journal.pone.0018568
64. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 2009; 106:14622-14627;PMID:19667187;http://dx.doi.org/10.1073/pnas.0906334106
65. Rudenko IN, Chia R, Cookson MR. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med 2012; 10:20;PMID:22361010;http://dx.doi.org/10.1186/1741-7015-10-20